お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
762883

世界の癌ワクチン市場調査と予測

Global Cancer Vaccine Market Research and Forecast, 2018-2023

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.68円
世界の癌ワクチン市場調査と予測
出版日: 2018年11月02日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の癌ワクチン市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 調査サマリー

第2章 市場概要と考察

  • 定義
  • アナリストの考察と現在の市場動向
    • 主な調査結果
    • 提言
    • 結論
  • 法規制

第3章 市場決定因子

  • 促進因子
  • 阻害因子
  • 機会

第4章 市場セグメンテーション

  • タイプ別市場
    • 予防ワクチン
    • 治療ワクチン
  • 技術別市場
    • 樹状細胞ワクチン
    • 結合ワクチン
    • 不活化ワクチン
    • 生ワクチン
    • 組み換えベクターワクチン
    • サブユニットワクチン
    • 合成ワクチン
    • トキソイドワクチン
  • エンドユーザー別市場
    • 病院・クリニック
    • 研究機関
    • 製薬会社・バイオテクノロジー企業

第5章 競合環境

  • 主な戦略分析
  • 主要企業分析

第6章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 企業のプロファイル

図表

List of Tables

  • TABLE # 1 GLOBAL CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLIONS)
  • TABLE # 2 GLOBAL PREVENTIVE VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 3 GLOBAL THERAPEUTIC VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 4 GLOBAL CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLIONS)
  • TABLE # 5 GLOBAL DENDRITIC CELL VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 6 GLOBAL CONJUGATE VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 7 GLOBAL INACTIVATED VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 8 GLOBAL LIVE ATTENUATED VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 9 GLOBAL RECOMBINANT VECTOR VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 10 GLOBAL SUBUNIT VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 11 GLOBAL SYNTHETIC VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 12 GLOBAL TOXOID VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 13 GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLIONS)
  • TABLE # 14 GLOBAL HOSPITALS & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 15 GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 16 GLOBAL PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 17 GLOBAL OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLIONS)
  • TABLE # 18 GLOBAL CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLIONS)
  • TABLE # 19 NORTH AMERICA CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 20 NORTH AMERICA CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
  • TABLE # 21 NORTH AMERICA CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)
  • TABLE # 22 NORTH AMERICA CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 23 EUROPE CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 24 EUROPE CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)
  • TABLE # 25 EUROPE CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
  • TABLE # 26 EUROPE CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 27 ASIA-PACIFIC CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 28 ASIA-PACIFIC CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
  • TABLE # 29 ASIA-PACIFIC CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)
  • TABLE # 30 ASIA-PACIFIC CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 31 REST OF THE WORLD CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 32 REST OF THE WORLD CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017-2023 ($ MILLION)
  • TABLE # 33 REST OF THE WORLD CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY TYPE, 2017 AND 2023 (IN %)
  • FIGURE # 2 GLOBAL CANCER VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2017 AND 2023 (IN %)
  • FIGURE # 3 GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017 AND 2023 (IN %)
  • FIGURE # 4GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017 AND 2023 (IN %)
  • FIGURE # 5 NORTH AMERICA CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 6 US CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 7 CANADA CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 8 EUROPEAN CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 9 UK CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 10 FRANCE CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 11 GERMANY CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 12 ITALY CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 13 SPAIN CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 14 ROE CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 15 ASIA-PACIFIC CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 16 INDIA CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 17 CHINA CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 18 JAPAN CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 19 REST OF ASIA-PACIFIC CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
  • FIGURE # 20 REST OF THE WORLD CANCER VACCINES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
目次
Product Code: OMR2018407

Cancer vaccines are biologics that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They are used for both adults and children. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. This is creating higher demands for cancer vaccines across the globe. The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the adoption of other forms of cancer immunotherapy treatments.

The factors contributing to the growth of the market are the high prevalence rate of cancer globally, innovative cancer vaccines, and increasing healthcare expenditure in developing countries. Technological advancements in vaccine manufacturing are further augmenting the growth of the cancer vaccine market. The promising pipeline vaccines are expected to propel the growth of the market in the future. Increasing awareness for cancer therapies will augment the market growth. However, strict and complex regulatory policies delay the reach of vaccines in the market. The storage of vaccines adds extra maintenance costs as proper temperature conditions are needed for its storage. These are hindering the growth of the market.

The cancer vaccine market is segmented on the basis of type, end-user, and technology. On the basis of the type of cancer vaccines, the market is segmented into preventive and therapeutic vaccines. On the basis of technology, the market is segmented into dendritic cell vaccines, conjugate vaccines, inactivated vaccines, live attenuated vaccines, recombinant vector vaccines, subunit vaccines, synthetic vaccines, and toxoid vaccines. Based on geography, North America dominates the market for cancer vaccines followed by Europe. This can be accounted to the presence of all the major life science companies in this region. Asia-Pacific region is estimated to be the fastest growing market for the forecast period due to its increasing healthcare expenditure in emerging countries such as India and China.

The companies contributing to the growth of global cancer vaccine market are AstraZeneca PLC, Bristol-Myers Squibb, Argos Therapeutics, Inc., Merck & Co. Inc., Immatics Biotechnologies GmbH, and Dendreon Pharmaceuticals LLC. In October 2017, Eli Lilly and Company and CureVac AG entered into a strategic alliance for the commercialization of five cancer vaccine products based on CureVac's patent RNActive technology.

Research methodology

The market study of the global cancer vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • An authentic database such as the National Society of Genetic Counselors, American Medical Association (AMA) and so on.
  • Company websites and their product/ services catalog.

The report is intended for biotechnology and life science companies, research institutes and government organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, growth opportunity in the market, product types. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market segmentation

1. Global cancer vaccine market by type

2. Global cancer vaccine market by technology

3. Global cancer vaccine market by end-user

THE REPORT COVERS

  • Comprehensive research methodology of global cancer vaccine market.
  • This report also includes a detailed and extensive market overview with analyst insights & key market trends.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global cancer vaccine market.
  • Insights about market determinants which are stimulating the global cancer vaccine market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Definition
  • 2.2. Analyst Insights & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendation
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Market Determinants

  • 3.1. Motivators
    • 3.1.1. High Prevalence Rate of Cancer Globally
    • 3.1.2. Development of Cancer Vaccines
    • 3.1.3. Increasing Healthcare Expenditure in Developing Countries
    • 3.1.4. Technological Advancements in Vaccine Manufacturing
  • 3.2. Restraints
    • 3.2.1. High Cost of Immunization
    • 3.2.2. Strict and Complex Regulatory Policies
  • 3.3. Opportunities
    • 3.3.1. Increasing Awareness for Cancer Therapies
    • 3.3.2. Extensive Funding for Cancer Vaccine Research

4. Market Segmentation

  • 4.1. Global Cancer Vaccine Market by Type
    • 4.1.1. Preventive Vaccines
    • 4.1.2. Therapeutic vaccines
  • 4.2. Global Cancer Vaccine Market by Technology
    • 4.2.1. Dendritic Cell Vaccines
    • 4.2.2. Conjugate Vaccines
    • 4.2.3. Inactivated Vaccines
    • 4.2.4. Live Attenuated Vaccines
    • 4.2.5. Recombinant Vector Vaccines
    • 4.2.6. Subunit Vaccines
    • 4.2.7. Synthetic Vaccines
    • 4.2.8. Toxoid Vaccines
  • 4.3. Global Cancer Vaccine Market by End-User
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Research Institutes
    • 4.3.3. Pharmaceuticals & Biotechnology Companies
    • 4.3.4. Others

5. Competitive Landscape

  • 5.1. Key Strategy Analysis
  • 5.2. Key Company Analysis

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. United Kingdom
    • 6.2.2. France
    • 6.2.3. Germany
    • 6.2.4. Italy
    • 6.2.5. Spain
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. India
    • 6.3.2. China
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Arbutus Biopharma Corp.
  • 7.2. Argos Therapeutics, Inc.
  • 7.3. Bristol-Myers Squibb Company
  • 7.4. CureVac AG
  • 7.5. Dendreon Pharmaceuticals LLC
  • 7.6. Eli Lilly and Company
  • 7.7. GE Healthcare Life Sciences
  • 7.8. GlaxoSmithKline PLC
  • 7.9. Immatics Biotechnologies GmbH
  • 7.10. Immutep S.A.
  • 7.11. Invectys SA
  • 7.12. Janssen Pharmaceuticals, Inc.
  • 7.13. MaxiVAX
  • 7.14. Merck & Co. Inc.
  • 7.15. Mitsubishi Tanabe
  • 7.16. Moderna, Inc.
  • 7.17. NantWorks, LLC
  • 7.18. Nouscom
  • 7.19. Novartis International AG
  • 7.20. OncBioMune Pharmaceuticals Inc.
  • 7.21. Pfizer, Inc.
  • 7.22. Roche Holding AG
  • 7.23. Takeda Pharmaceuticals Company Ltd.
  • 7.24. Targovax ASA
  • 7.25. Vaxil Bio Ltd.
  • 7.26. ViciniVax BV
  • 7.27. Virometix AG
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.